Doripenem

Generic Name
Doripenem
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C15H24N4O6S2
CAS Number
148016-81-3
Unique Ingredient Identifier
BHV525JOBH
Background

Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem c...

Indication

用于敏感的革兰阳性菌、阴性菌和厌氧菌所致的呼吸系统、尿道、皮肤软组织、脑组织感染、败血症、细菌性心内膜炎等全身性严重感染，各种外科手术后感染等。

Associated Conditions
Bacterial Infections, Catheter-related Bloodstream Infection (CRBSI) NOS, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Pyelonephritis
Associated Therapies
-
Clinical Trials
Related News

A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections

First Posted Date
2010-04-26
Last Posted Date
2014-07-15
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
41
Registration Number
NCT01110382

Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients

Phase 4
Completed
Conditions
Sepsis
Interventions
Drug: Doripenem
First Posted Date
2009-12-09
Last Posted Date
2014-01-27
Lead Sponsor
Emory University
Target Recruit Count
30
Registration Number
NCT01027897
Locations
🇺🇸

Grady Memorial Hospital, Atlanta, Georgia, United States

PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region

First Posted Date
2009-09-29
Last Posted Date
2024-11-19
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
216
Registration Number
NCT00986102

A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections

First Posted Date
2009-08-26
Last Posted Date
2013-10-30
Lead Sponsor
Janssen-Cilag Ltd.,Thailand
Target Recruit Count
270
Registration Number
NCT00965848

Doripenem Intrapulmonary Pharmacokinetics in Healthy Adult Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Doripenem
First Posted Date
2009-06-22
Last Posted Date
2013-03-14
Lead Sponsor
Keith A. Rodvold
Target Recruit Count
40
Registration Number
NCT00925392
Locations
🇺🇸

Pulmonary Associates, PA, Phoenix, Arizona, United States

To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia

First Posted Date
2008-01-10
Last Posted Date
2012-12-28
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
274
Registration Number
NCT00589693

A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia

First Posted Date
2007-08-13
Last Posted Date
2019-03-19
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
146
Registration Number
NCT00515034

An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia

First Posted Date
2007-07-18
Last Posted Date
2013-09-25
Lead Sponsor
PriCara, Unit of Ortho-McNeil, Inc.
Target Recruit Count
185
Registration Number
NCT00502801

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

First Posted Date
2005-09-29
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
483
Registration Number
NCT00229060

Doripenem in the Treatment of Ventilator-Associated Pneumonia

Phase 3
Completed
Conditions
Pneumonia
Ventilators, Mechanical
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
318
Registration Number
NCT00211016
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy